Search - tctmd.com

Displaying 1 - 20 of 77

Sort: Relevancy | Date

DOAC May Be Safer Than DAPT After Left Atrial Appendage Closure ANDES

News Conference News TCT 2025

DOAC May Be Safer Than DAPT After Left Atrial Appendage Closure: ANDES

Yael L. Maxwell

November 04, 2025

ESC/EACTS Release New Valvular Heart Disease Guidelines

News Conference News ESC 2025

ESC/EACTS Release New Valvular Heart Disease Guidelines

Yael L. Maxwell

September 03, 2025

Prompt TAVI Benefits Asymptomatic AS Patients Regardless of Guideline Indication

News Conference News NY Valves 2025

Prompt TAVI Benefits Asymptomatic AS Patients Regardless of Guideline Indication

June 27, 2025

Stroke Risk Higher With TAVI vs Surgery at 5 Years: UK TAVI

News Conference News EuroPCR 2025

Stroke Risk Higher With TAVI vs Surgery at 5 Years: UK TAVI

Michael O'Riordan

May 23, 2025

Paclitaxel or Sirolimus: New PAD Studies Shed Light on Choices

News Conference News CX Symposium 2025

Paclitaxel or Sirolimus: New PAD Studies Shed Light on Choices

April 23, 2025

More ALIGN-AR Data Bolster Potential for a Dedicated AR Device

News Conference News ACC 2025

More ALIGN-AR Data Bolster Potential for a Dedicated AR Device

Yael L. Maxwell

March 30, 2025

Need for Rethink of Discharge Medications After LAA Closure? EMERGE

News Conference News CRT 2025

Need for Rethink of Discharge Medications After LAA Closure? EMERGE

March 12, 2025

AGENT IDE: DCB Performance for In-Stent Restenosis Lasts Out to 2 Years

News Conference News CRT 2025

AGENT IDE: DCB Performance for In-Stent Restenosis Lasts Out to 2 Years

March 10, 2025

Pooled All-Female Analysis Support Benefits of TAVI Over SAVR

News Conference News TCT 2024

Pooled All-Female Analysis Support Benefits of TAVI Over SAVR

November 01, 2024

SIRONA: Sirolimus and Paclitaxel DCBs Offer Similar Patency, Function in PAD

News Conference News TCT 2024

SIRONA: Sirolimus and Paclitaxel DCBs Offer Similar Patency, Function in PAD

October 29, 2024

Protecting Coronary Access After TAVI: Valve Choice Clues From CAVEAT

News Conference News TCT 2024

Protecting Coronary Access After TAVI: Valve Choice Clues From CAVEAT

Michael O'Riordan

October 27, 2024

TEER May Be Option for Primary MR and ‘Red Zone’ Anatomy

News Conference News NY Valves 2024

TEER May Be Option for Primary MR and ‘Red Zone’ Anatomy

June 11, 2024

Another Win for TAVI in Low-to-Intermediate Risk Patients

News Conference News ACC 2024

Another Win for TAVI in Patients at Low-to-Intermediate Risk: DEDICATE-DZHK6

Yael L. Maxwell

April 08, 2024

Early Empagliflozin Doesn’t Curb HF Hospitalizations, Deaths Post-MI: EMPACT-MI

News Conference News ACC 2024

Early Empagliflozin Doesn’t Curb HF Hospitalizations, Deaths Post-MI: EMPACT-MI

April 06, 2024

SAVR After Failed TAVI on the Rise, With High Mortality

News Conference News STS 2024

SAVR After Failed TAVI on the Rise, With High Mortality

Yael L. Maxwell

February 05, 2024

TAVI, SAVR Almost Equally Performed in California Patients Under 60

News Conference News STS 2024

TAVI, SAVR Almost Equally Performed in California Patients Under 60

Yael L. Maxwell

February 01, 2024

BIOSTEMI: Degradable-Polymer, Ultrathin-Strut DES Shows No Late Catch-up at 5 Years

News Conference News TCT 2023

BIOSTEMI: Degradable-Polymer, Ultrathin-Strut DES Shows No Late Catch-up at 5 Years

October 27, 2023

‘Light at the End of the Tunnel’ for In-Stent Restenosis: AGENT IDE Wins Big

News Conference News TCT 2023

‘Light at the End of the Tunnel’ for In-Stent Restenosis: AGENT IDE Wins Big

October 25, 2023

OCT, IVUS Both Seem to Be Good Options for Complex Coronary Lesions

News Conference News TCT 2023

OCT, IVUS Both Seem to Be Good Options for Complex Coronary Lesions

October 23, 2023

AUTHEARTVISIT Reignites RCT vs Real-world Data Debate for AV Repair

News Conference News EACTS 2023

AUTHEARTVISIT Reignites RCT vs Real-world Data Debate for AV Repair

Michael O'Riordan

October 09, 2023

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.